Ankylosing Spondylitis: How Have Biological Therapies Affected the Market?

Title	Published	Price
Prostate Cancer Drug Discoveries: What the Future Holds By: Espicom Healthcare Intelligence Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about \| more... Search inside this report	11/5/2009	$2,460.00
BI for Drug Development: Oracle Introduces Clinical Development Analytics By: IDC This IDC Health Insights Perspective highlights the announcement of a dedicated life science business intelligence (BI) solution introduced recently at Oracle OpenWorld 2009 that promises to deliver actionable insights into clinical development processes. Oracle Clinical \| more... Search inside this report	11/1/2009	$1,500.00
CDK Inhibitors Patent Landscape 2009 By: France Innovation Scientifique et Transfer IP Overview presents a patent landscape analysis of the CDK Inhibitor field. Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative \| more... Search inside this report	10/29/2009	$1,645.00
Protein Kinase Therapeutics in Oncology - Where to Commercialize? By: BioSeeker Group AB This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of \| more...	10/29/2009	$3,500.00
Antidiabetics in Australia Market Forecast By: Datamonitor Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest \| more...	10/20/2009	$5,700.00
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases By: Decision Resources Introduction Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated measures to detect diseases earlier \| more...	10/13/2009	$2,250.00
Patent Foramen Ovale Closure Market: Clinical Trial Outcomes to Play a Key Role By: GlobalData Summary Over the last decade there has been considerable evidence gathered, relating Patent Foramen Ovales (PFO) to migraines, cryptogenic stroke and decompression sickeness. There is an increased frequency of PFO in patients suffering from migraine- a \| more...	10/12/2009	$500.00
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market By: Datamonitor Introduction Drugs with new mechanisms, in particular Pfizer’s oral JAK inhibitor CP-690,550 and Chugai/Roche’s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. \| more...	10/12/2009	$11,400.00
Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth By: Datamonitor Introduction The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches \| more...	10/8/2009	$15,200.00
Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market By: Datamonitor Introduction With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial \| more...	10/8/2009	$15,200.00

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2